Federal regulators approved a first-of-its-kind cholesterol medication from Merck that rivals the effectiveness of powerful drugs already on the market. The Food and Drug Administration (FDA) greenlit the once-daily pill called Lipfendra. Lipfendra reduces “bad,” or low-density lipoprotein cholesterol (LDL-C) in adults by inhibiting the production of PCSK9 proteins. Lipfendra is the first drug that…